https://aptekium.com/2026/04/biogen-ionis-biib094-lrrk2-parkinson-research-2026.html
Biogen и Ionis Pharmaceuticals замедляют развитие болезни Паркинсона - АПТЕКИУМ
Apr 14, 2026 - Biogen и Ionis успешно испытали BIIB094: снижение белка LRRK2 на 59% открывает путь к патогенетической терапии болезни Паркинсона.
ionis pharmaceuticalsbiogen
https://www.pharmtech.com/view/ionis-pharmaceuticals-receives-orphan-drug-designation-httrx
Ionis Pharmaceuticals Receives Orphan Drug Designation for HTTRx | Pharmaceutical Technology
Oct 8, 2026 - Ionis Pharmaceuticals receives orphan drug designation for HTTRx for the treatment of Huntington’s disease.
orphan drug designationionis pharmaceuticalsreceivestechnology
https://dev.form4.levelfields.ai/company/0000874015
IONIS PHARMACEUTICALS INC (IONS) Insider Trading | LevelFields AI
SEC Form 4 insider trading activity for IONIS PHARMACEUTICALS INC (IONS).
ionis pharmaceuticalsinsider tradinglevelfields aiincions